Results 21 to 30 of about 124,462 (290)
Platelets, 2021 Most agonists stimulate platelet Ca2+ rises via G-protein coupled receptors (GPCRs) or ITAM-linked receptors (ILRs). Well studied are the GPCRs stimulated by the soluble agonists thrombin (PAR1, PAR4), ADP (P2Y1, P2Y12), and thromboxane A2 (TP ...
Delia I. Fernández +2 more
doaj +1 more source
Variation in Human Platelet Glycoprotein VI Content Modulates Glycoprotein VI–Specific Prothrombinase Activity [PDF]
Arteriosclerosis, Thrombosis, and Vascular Biology, 2001 Glycoprotein VI (GPVI) is a platelet-specific receptor for collagen that figures prominently in signal transduction. An addition to binding to type I and III collagens, GPVI is also bound specifically by collagen-related peptide and convulxin (CVX), a snake venom protein.
K, Furihata +3 more
openaire +2 more sources
Absence of bleeding upon dual antiplatelet therapy in a patient with a immune GPVI deficiency
Platelets, 2021 Acquired deficiencies in platelet glycoprotein VI are rare and have not been found associated with other defects. Here we report the case of a 64-year old male patient presenting an immune GPVI deficiency associated to a mutation in the alpha-actinin ...
Stéphane Loyau Inserm +5 more
doaj +1 more source
Efficient inhibition of collagen-induced platelet activation and adhesion by LAIR-2, a soluble Ig-like receptor family member. [PDF]
PLoS ONE, 2010 LAIR-1 (Leukocyte Associated Ig-like Receptor -1) is a collagen receptor that functions as an inhibitory receptor on immune cells. It has a soluble family member, LAIR-2, that also binds collagen and can interfere with LAIR-1/collagen interactions ...
Peter J Lenting +4 more
doaj +1 more source
Platelet glycoprotein VI‐related clinical defects [PDF]
British Journal of Haematology, 2007 SummaryHuman patients with defects associated with the platelet collagen receptor, glycoprotein (GP)VI, are rare and usually described as having a mild bleeding disorder. However, here we review clinical profiles of patients with familial or acquired GPVI defects, revealing the bleeding defect is often severe and associated with immune dysfunction ...
Jane F, Arthur +2 more
openaire +2 more sources
Platelets, 2023 The association between endometriosis and autoimmune diseases is well known, however no acquired platelet function defect has been described so far. We describe the case of two patients with endometriosis associated with an antiplatelet glycoprotein VI ...
Stéphane Loyau +12 more
doaj +1 more source
Differential effects of reduced glycoprotein VI levels on activation of murine platelets by glycoprotein VI ligands [PDF]
Biochemical Journal, 2002 We have investigated the effects of decreased levels of the complex between glycoprotein VI (GPVI) and the Fc receptor γ-chain (FcRγ) on responses to collagen and GPVI-specific ligands in murine platelets. We show that levels of GPVI—FcRγ of the order of 50% and 20% of wild-type levels caused 2- and 5-fold shifts to the right respectively in the dose ...
Snell, D.C. +7 more
openaire +2 more sources
Glycoprotein VI interplay with fibrin(ogen) in thrombosis
Journal of Thrombosis and Haemostasis, 2023 Platelets play a central role in the arrest of bleeding. The ability of platelets to engage with extracellular matrix proteins of the subendothelium has long been recognized as a pivotal platelet attribute, underpinning adequate hemostasis. The propensity of platelets to rapidly bind and functionally respond to collagen was one of the earliest ...
Pierre H, Mangin +3 more
openaire +2 more sources
Psoralen and ultraviolet A light treatment directly affects phosphatidylinositol 3-kinase signal transduction by altering plasma membrane packing [PDF]
, 2016 Psoralen and ultraviolet A light (PUNTA) are used to kill pathogens in blood products and as a treatment of aberrant cell proliferation in dermatitis, cutaneous T-cell lymphoma, and graft versus-host disease.
Compernolle, Veerle +7 more
core +2 more sources
Ibrutinib-associated alveolar hemorrhage and spontaneous hemothorax
Polish Journal of Thoracic and Cardiovascular Surgery, 2022 Ibrutinib is an irreversible inhibitor of Bruton’s tyrosine kinase (BTK), a cytoplasmic tyrosine kinase of the Tec family, which plays an important role in the B-cell receptor signaling pathway [1].
Ismail Tombul +5 more
doaj +1 more source